Avalo Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Avalo Therapeutics

01/05/2023 17:46

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 3
(estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
14.7% decrease in revenue to $1 million from $1.17 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Avalo Therapeutics
Inc is
for a loss of 97 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 5.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $10​, above​ its last closing price
of $2.91. ​​​

This summary was machine generated May 1 at 16:46 GMT.  All
figures in US dollars  unless otherwise stated